Project Farma (PF)’s Post

Is there healthcare allocation beyond index heavyweight Novo Nordisk? Portfolio manager Mark Denham says yes. 🔎 Read more about embracing innovation and the low correlation of biotech relative to pharma, as well as the STOXX 600, in our recent article about Healthcare’s innovative underbelly → https://okt.to/ZYRVNp #assetmanagement #marketingcommunication #finance #investment #investinginyourinterest #biotech

Is there healthcare allocation beyond index heavyweight Novo Nordisk? Portfolio manager Mark Denham says yes. 🔎 Read more about embracing innovation and the low correlation of biotech relative to pharma, as well as the STOXX 600, in our recent article about Healthcare’s innovative underbelly → https://okt.to/5R76a2 #assetmanagement #marketingcommunication #finance #investment #investinginyourinterest #biotech

Is there healthcare allocation beyond index heavyweight Novo Nordisk? Portfolio manager Mark Denham says yes. 🔎 Read more about embracing innovation and the low correlation of biotech relative to pharma, as well as the STOXX 600, in our recent article about Healthcare’s innovative underbelly → https://okt.to/lTxRXQ #assetmanagement #marketingcommunication #finance #investment #investinginyourinterest #biotech

For pharma companies, biotech assets present a huge opportunity to strengthen pipelines with reduced risk. But finding the right assets at a reasonable price is no mean feat. How can you discover hidden gems – or even the next blockbuster? In this Evaluate blog post, Pengfei Lu shares his tips for dealmaking success. ow.ly/ZAYB30sHTvR

Is there healthcare allocation beyond index heavyweight Novo Nordisk? Portfolio manager Mark Denham says yes. 🔎 Read more about embracing innovation and the low correlation of biotech relative to pharma, as well as the STOXX 600, in our recent article about Healthcare’s innovative underbelly → https://okt.to/8WMLIr #assetmanagement #marketingcommunication #finance #investment #investinginyourinterest #biotech

Is there healthcare allocation beyond index heavyweight Novo Nordisk? Portfolio manager Mark Denham says yes. 🔎 Read more about embracing innovation and the low correlation of biotech relative to pharma, as well as the STOXX 600, in our recent article about Healthcare’s innovative underbelly → https://okt.to/ZEMHDU #assetmanagement #marketingcommunication #finance #investment #investinginyourinterest #biotech

For pharma companies, biotech assets present a huge opportunity to strengthen pipelines with reduced risk. But finding the right assets at a reasonable price is no mean feat. How can you discover hidden gems – or even the next blockbuster? In our latest blog post, Pengfei Lu shares his tips for dealmaking success. https://lnkd.in/eRYQtFy5

Epoch 51: Biotech Archetypes 👉 FED policy impact on biotech 2025 👉 Biotech vs pharma performance 👉 Downrounds 👉 Biotech company builds https://lnkd.in/g5-WBymn

At AD Marketing, we believe great ideas power exceptional campaigns. Explore our proven methods for sparking creativity and driving innovation in biotech, pharma, and beyond. Let's brainstorm your next breakthrough. #Ideation #MarketingStrategy"

🔬 Biotech News: Genmab Acquires ProfoundBio, Signals More M&A Ahead TL;DR: Genmab has acquired ProfoundBio and is actively exploring additional M&A opportunities, according to their CFO. 🔍 Industry Impact: This strategic move reflects a broader consolidation trend in biotech, as companies seek to: • Enhance research capabilities • Expand product pipelines • Strengthen competitive positioning 💡 Strategic Takeaways for Biotech Leaders: - Evaluate M&A opportunities aligned with core operations - Consider portfolio diversification potential - Assess geographic expansion possibilities - Focus on innovation acceleration - Balance strategic growth with resource management The biotech landscape is evolving rapidly. How is your organization approaching strategic growth in 2024? Share your thoughts below. 👇 #Biotech #MergersAndAcquisitions #BiotechStrategy #PharmaTrends #pharma #biotech #medicinetomarket